Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome

(2014) A. Brioli et al.   BLOOD

Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma

(2014) Jae-Sook Ahn et al.   Clinical Lymphoma Myeloma & Leukemia

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Current strategies for treatment of relapsed/refractory multiple myeloma

(2014) Jacob P Laubach et al.   Expert Review of Hematology

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

(2013) M. Wang et al.   BLOOD

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

(2013) H. Ludwig et al.   BLOOD

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma

(2013) Alina S. Gerrie et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077

(2013) Wolfram Pönisch et al.   BRITISH JOURNAL OF HAEMATOLOGY

Autologous retransplantation for patients with recurrent multiple myeloma

(2013) Leopold Sellner et al.   CANCER

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

(2013) R. Niesvizky et al.   CLINICAL CANCER RESEARCH

Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib

(2013) Jan Smetana et al.   Clinical Lymphoma Myeloma & Leukemia

Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution

(2013) N. Tovar et al.   HAEMATOLOGICA

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

(2013) M. A. Dimopoulos et al.   HAEMATOLOGICA

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

(2013) Meletios Dimopoulos et al.   LANCET ONCOLOGY

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

(2013) A J Jakubowiak et al.   LEUKEMIA

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

(2013) E M Ocio et al.   LEUKEMIA

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

(2013) M Offidani et al.   Blood Cancer Journal

Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases

(2012) Leo Rasche et al.   ANNALS OF HEMATOLOGY

Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma

(2012) Emilie Lemieux et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

(2012) R. Vij et al.   BLOOD

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

(2012) P. G. Richardson et al.   BLOOD

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

(2012) S. Lentzsch et al.   BLOOD

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

(2012) M. Cavo et al.   BLOOD

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study

(2012) Andrzej J. Jakubowiak et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma

(2012) Donna M. Weber et al.   Clinical Lymphoma Myeloma & Leukemia

New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors

(2012) Michele Cea et al.   CURRENT PHARMACEUTICAL DESIGN

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2012) Laurent Garderet et al.   JOURNAL OF CLINICAL ONCOLOGY

Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

(2012) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse

(2012) Xenofon Papanikolaou et al.   LEUKEMIA & LYMPHOMA

Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability

(2011) Francesca Patriarca et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

(2011) Victor H. Jimenez-Zepeda et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

(2011) S. J. Harrison et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Treatment Options for Relapsed and Refractory Multiple Myeloma

(2011) Sagar Lonial et al.   CLINICAL CANCER RESEARCH

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial

(2011) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up

(2011) Bo Björkstrand et al.   JOURNAL OF CLINICAL ONCOLOGY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program

(2011) G. Damaj et al.   LEUKEMIA & LYMPHOMA

Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland

(2011) I. Hrusovsky et al.   ONCOLOGY

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma

(2010) C. S. Chim et al.   ANNALS OF HEMATOLOGY

Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma

(2010) Yvonne A. Efebera et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study

(2010) Stephen A. Schey et al.   BRITISH JOURNAL OF HAEMATOLOGY

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma

(2010) Avichai Shimoni et al.   CANCER

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

(2010) Jean-Luc Harousseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma

(2010) Marco Ladetto et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma

(2010) A Palumbo et al.   LEUKEMIA

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

(2010) H Avet-Loiseau et al.   LEUKEMIA

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

(2010) M A Dimopoulos et al.   LEUKEMIA

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (

(2010) Christopher P. Venner et al.   LEUKEMIA & LYMPHOMA

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

(2009) Yeo-Kyeoung Kim et al.   ANNALS OF HEMATOLOGY

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

(2009) D. Reece et al.   BLOOD

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)

(2009) S. Knop et al.   BLOOD

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma

(2009) Niels W.C.J. van de Donk et al.   BRITISH JOURNAL OF HAEMATOLOGY

Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation

(2009) Nicolaus Kröger et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma

(2008) A. Palumbo et al.   ANNALS OF ONCOLOGY

First thalidomide clinical trial in multiple myeloma: a decade

(2008) F. van Rhee et al.   BLOOD

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

(2008) R L Olin et al.   BONE MARROW TRANSPLANTATION

Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma

(2008) H de Lavallade et al.   BONE MARROW TRANSPLANTATION

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

(2008) Joseph R. Mikhael et al.   BRITISH JOURNAL OF HAEMATOLOGY

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

(2008) Marie von Lilienfeld-Toal et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma

(2008) Donna E. Reece et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

(2008) S. Vincent Rajkumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE